Direct Identification of Yeasts from Blood Cultures and Body Fluids Using MALDI-TOF MS with Concurrent Antifungal...

Area of Science:

• Clinical Microbiology
• Infectious Diseases
• Diagnostic Technology

Background:

• Invasive fungal infections are increasing, alongside antifungal resistance.
• Timely, targeted antifungal therapy requires rapid pathogen identification and susceptibility testing.
• Current methods can be time-consuming, delaying appropriate treatment.

Purpose of the Study:

• To evaluate a MALDI-TOF MS-based method for rapid yeast identification from clinical samples.
• To assess the performance of direct antifungal susceptibility testing (Direct-AFST) coupled with MALDI-TOF MS.
• To determine the clinical utility of this combined approach for improving patient management.

Main Methods:

• MALDI-TOF MS was used to identify over 700 yeast isolates from blood cultures and body fluids.
• Direct-AFST was performed on 250 isolates and compared to conventional culture-based AFST (Culture-AFST).
• Evaluation included diverse Candida and non-Candida species, assessing method performance across different sample types.

Main Results:

• MALDI-TOF MS provided accurate and rapid yeast identification directly from positive blood cultures.
• Direct-AFST demonstrated excellent categorical agreement with Culture-AFST.
• The combined method proved effective irrespective of microbial load or sample preparation.

Conclusions:

• MALDI-TOF MS is clinically valuable for rapid yeast identification from blood cultures.
• Direct-AFST shows significant potential for early antifungal resistance detection.
• This integrated approach can substantially reduce diagnostic turnaround times, optimizing patient management.